These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 32428427)

  • 21. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
    Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
    Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of health state selection on the valuation of EQ-5D.
    Chuang LH; Kind P
    Med Decis Making; 2011; 31(1):186-94. PubMed ID: 20671210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D.
    Feng Y; Herdman M; van Nooten F; Cleeland C; Parkin D; Ikeda S; Igarashi A; Devlin NJ
    Qual Life Res; 2017 Aug; 26(8):2067-2078. PubMed ID: 28343350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L.
    Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL
    Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping the COPD Assessment Test onto EQ-5D.
    Hoyle CK; Tabberer M; Brooks J
    Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Social valuation of EQ-5D health states: the Chilean case.
    Zarate V; Kind P; Valenzuela P; Vignau A; Olivares-Tirado P; Munoz A
    Value Health; 2011 Dec; 14(8):1135-41. PubMed ID: 22152184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valuation of Quality Weights for EuroQol 5-Dimensional Health States With the Time Trade-Off Method in the Capital of Iran.
    Goudarzi R; Sari AA; Zeraati H; Rashidian A; Mohammad K; Amini S
    Value Health Reg Issues; 2019 May; 18():170-175. PubMed ID: 31096140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV.
    Joyce VR; Sun H; Barnett PG; Bansback N; Griffin SC; Bayoumi AM; Anis AH; Sculpher M; Cameron W; Brown ST; Holodniy M; Owens DK
    MDM Policy Pract; 2017; 2(2):2381468317716440. PubMed ID: 30288427
    [No Abstract]   [Full Text] [Related]  

  • 29. Between-country heterogeneity in EQ-5D-3L scoring algorithms: how much is due to differences in health state selection?
    Pullenayegum EM; Perampaladas K; Gaebel K; Doble B; Xie F
    Eur J Health Econ; 2015 Nov; 16(8):847-55. PubMed ID: 25252970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
    Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
    Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing outcomes for cost-utility analysis in mental health interventions: mapping mental health specific outcome measure GHQ-12 onto EQ-5D-3L.
    Lindkvist M; Feldman I
    Health Qual Life Outcomes; 2016 Sep; 14(1):134. PubMed ID: 27644119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantifying the Relationship between Capability and Health in Older People: Can't Map, Won't Map.
    Franklin M; Payne K; Elliott RA
    Med Decis Making; 2018 Jan; 38(1):79-94. PubMed ID: 29056069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sample Size and Model Prediction Accuracy in EQ-5D-5L Valuations Studies: Expected Out-of-Sample Accuracy Based on Resampling with Different Sample Sizes and Alternative Model Specifications.
    Hansen TM; Stavem K; Rand K
    MDM Policy Pract; 2022; 7(1):23814683221083839. PubMed ID: 35281553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How is the most severe health state being valued by the general population?
    Gandhi M; Thumboo J; Wee HL; Luo N; Cheung YB
    Health Qual Life Outcomes; 2014 Oct; 12():161. PubMed ID: 25344269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toward a Smaller Design for EQ-5D-5L Valuation Studies.
    Yang Z; Luo N; Oppe M; Bonsel G; Busschbach J; Stolk E
    Value Health; 2019 Nov; 22(11):1295-1302. PubMed ID: 31708067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Experience-Based Value Set for the EQ-5D-5L in Germany.
    Leidl R; Reitmeir P
    Value Health; 2017 Sep; 20(8):1150-1156. PubMed ID: 28964448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
    Golicki D; Jakubczyk M; Graczyk K; Niewada M
    Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
    Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
    Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
    Yang Q; Yu XX; Zhang W; Li H
    Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimation of an Instrument-Defined Minimally Important Difference in EQ-5D-5L Index Scores Based on Scoring Algorithms Derived Using the EQ-VT Version 2 Valuation Protocols.
    Henry EB; Barry LE; Hobbins AP; McClure NS; O'Neill C
    Value Health; 2020 Jul; 23(7):936-944. PubMed ID: 32762996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.